Mycoplasma genitalium is very difficult to grow in culture but has been more able to be studied for disease associations since the advent of research molecular amplification assays. Polymerase chain reaction (PCR) and other molecular assays have demonstrated an association with adverse disease outcomes, such as urethritis or nongonococcal urethritis in men and adverse reproductive sequelae in women-for example, cervicitis, endometritis, and pelvic inflammatory disease (PID), including an association with risk for human immunodeficiency virus. The lack of commercially available diagnostic assays has limited widespread routine testing. Increasing reports of high rates of resistance to azithromycin detected in research studies have heightened the need available commercial diagnostic assays as well as standardized methods for detecting resistance markers. This review covers available molecular methods for the diagnosis of M. genitalium and assays to predict the antibiotic susceptibility to azithromycin.
The mollicute Mycoplasma genitalium is a fastidious obligate intracellular bacterium and is the smallest prokaryote capable of self-replication [1] . Its tiny genome is 580 kb long and contains 482 protein-coding genes [1, 2] . Although very difficult to grow, M. genitalium was first cultured by Tully et al [3] from urethral specimens obtained from men with urethritis (nongonococcal) in 1981. Tissue culture is used to enhance the recovery of the organism, but slow growth and cumbersome detection methods preclude the method's routine use for diagnosis [4] . The bacterium has been able to be better studied for disease associations since the advent of research molecular amplification assays, such as polymerase chain reaction (PCR) and transcription-mediated amplification assays (TMAs) [5] [6] [7] [8] [9] [10] . Since the availability of such molecular assays, the organism has been associated with many adverse disease outcomes, such as urethritis or nongonococcal urethritis in men and many adverse reproductive sequelae in women, including cervicitis, endometritis, and PID [11] [12] [13] [14] [15] [16] . There is also a strong association with risk for human immunodeficiency virus [17] . The lack of a Food and Drug Administration (FDA)-cleared diagnostic assay, however, has severely limited the availability of testing in symptomatic and asymptomatic high-risk individuals. Increasing the concerns for treatment of the diseases caused by M. genitalium are reports of rising rates of resistance to azithromycin [18] . The emerging role for M. genitalium as a sexually transmitted infection (STI) pathogen has been comprehensively reviewed by Taylor-Robinson and Jensen [19] and Manhart [11] . This review focuses on new molecular methods for the diagnosis of M. genitalium and assays to predict antibiotic susceptibility to azithromycin.
METHODS
A PubMed (US National Library of Medicine and the National Institutes of Health) search was conducted for literature published between 2000 and 2016 using the following search terms: Mycoplasma genitalium, M. genitalium, diagnosis, and detection. A list of 1003 published articles was retrieved. Articles were reviewed and analyzed for diagnostic methods by amplification and molecular methods, as well as for diagnosis of resistance markers.
RESULTS AND DISCUSSION

Diagnosis of Syndromes Associated With M. genitalium
Urethritis in men was the first syndrome associated with Mycoplasma. The diagnosis and causes of urethritis are well established and has been recently reviewed by Bachmann et al [20] . That review covered M. genitalium as an emerging cause of urethritis. Although many studies have used the urethral Gram stain criterion of ≥5 polymorphonuclear leukocytes per high-power field to diagnose urethritis, many chlamydia and possibly M. genitalium infections may be missed by this criterion, and now the Centers for Disease Control and Prevention recommend using ≥2 polymorphonuclear leukocytes per high-power field as the diagnostic threshold [20] . Persistence of urethritis after therapy has been especially associated with M. genitalium and may be due to suspected antibiotic resistance [21] [22] . However, there are other possible causes, including reinfection, noncompliance with therapy, drug resistance, or postinfectious immunologic reaction. Diagnosis of Mycoplasma infection and other STIs in women are less likely to be associated with specific symptomatic states and are often asymptomatic. Mycoplasma can be found in the vagina, cervix, and endometrium. Much new evidence has accumulated in the past few years implicating M. genitalium as an important cause of morbid effects in women [11, 12, 15] . (See article on the subject in this supplement.)
Diagnosis of M. genitalium by Molecular Methods
Although there are no FDA-cleared M. genitalium assays currently available in the United States, research assays based on nucleic acid amplification tests (NAATs) have been in use since the early 1990s and are highly sensitive and specific for detecting many infectious organisms, such as chlamydia, gonorrhea, and trichomonas, as well as M. genitalium [5] [6] [7] [8] [9] . The assay formulated by Jensen and colleagues [6] [7] [8] targeting a conserved region of the 16S ribosomal RNA (rRNA) gene have been widely used in research-based studies ( Table 1) .
The process for a laboratory to develop and use a research diagnostic test within a single laboratory requires extensive testing to demonstrate its accuracy and is known as a laboratory-developed test (LDT). LDTs are laboratory tests that hospitals, academic, and clinical laboratories develop as testing services according to their own procedures. They are often created in response to unmet clinical needs and may be used for precise diagnosis and for monitoring and guiding patient treatment. LDTs are also used to diagnose and assess diseases and disorders for which no FDA-authorized test kit currently exists, such as for rare diseases.
For laboratories in the United States to use research NAATs developed by a company, often termed "research-use only" (RUO) tests, for diagnosis and treatment of disease in patients seen in clinical settings, each laboratory must be internally validate the assay, similar to that procedure required for a LDT. This process involves each individual laboratory performing its own study to compare the RUO assay with another assay for the analyte or comparing the laboratory's individual results with those obtained by another laboratory, much like what the FDA would require for an LDT. This is an expensive process and not easily accomplished.
The next step on the path for performing commercialization is for a company to submit its test reagents to the FDA to obtain an analyte-specific reagent (ASR) status. This means that the company can sell the reagents but not as a "kit" with controls or controls. A laboratory would still have to perform a validation study, similar to the process for developing a LDR, to use the results of this assay clinically, that is, for treating patients Very few laboratories have done this. Only 1 company has achieved the ASR status in the United States with a TMA assay originally designed and offered as an RUO assay by the GenProbe/Hologic Company [9, 10] . Hardick et al reported the overall sensitivity and specificity of the RUO product in 607 persons as 98.1% and 98.1%, respectively, compared with 2 research assays (100% and 97.9% in urine samples from male subjects, respectively and 98.4% in vaginal swab samples) [9] . This M. genitalium TMA ASR assay is also now CE marked in Europe [23, 24] . It has been widely used for much Mycoplasma research and to study the epidemiology of M. genitalium [10, 13, 14, 21, 22] . The next step would be the performance of a FDA clinical trial, which is a costly process.
The term CE originated as an abbreviation of conformité Européenne, meaning European conformity, but the term is not defined as such in the relevant legislation. The CE marking is a symbol of free marketability in the European Economic Area (internal market). The CE mark on an assay in Europe is a manufacturer's declaration that the product complies with the essential requirements of the relevant European protection legislations. It signifies that products sold in the European Economic Area have been assessed to meet high safety, health, and environmental protection requirements. It ensures the free movement of the product within the European Union. No clinical validation against a reference standard is needed.
Fortunately, a large group of other diagnostic molecular methods, described below, have been developed both internationally and nationally, and some are beginning to receive the CE mark. Some of these hold great promise for diagnostic options for both research and clinical use. Several very new assays have also been developed (Table 1) .
When a new multiplex PCR assay, the STDFinder assay, was studied, it was reported to be 100% specific and 100% sensitive in detecting Mycoplasma, but only 3 cases were detected [25] .
The multiplex ligation-dependent probe amplification technology uses a single assay, which is able to amplify up to 45 different targets simultaneously using 1 universal primer set in the final amplification.
An early evaluation of the performance of the Bio-Rad Dx CT/NG/MG assay for the detection of Chlamydia trachomatis, M. genitalium, and Neisseria gonorrhoeae in urogenital samples indicated that, compared with an in-house TaqMan PCR assay for M. genitalium, the new assay had a specificity for detecting M. genitalium of 99.5% for swab samples and 100% for urine samples from female subjects, but very few cases of Mycoplasma were detected [26] .
Müller et al developed and validated a real-time quantitative PCR (qPCR) assay to determine the M. genitalium bacterial load in endocervical swab samples, based on amplification of the pdhD gene that encodes dihydrolipoamide dehydrogenase, using the Rotor-Gene platform [27] . The assay demonstrated a detection limit of 300 genome copies/mL using the G37 M. genitalium genomic DNA (ASTCC 33530D). The assay amplified an 82-base pair fragment of the pdhD gene of M. genitalium (nucleotides corresponding to the sequence with GenBank No. L43967.2). The assay was specific for M. genitalium DNA and did not amplify the DNA from other Mycoplasma and Ureaplasma species, compared with a commercial assay (Sacace Biotechnologies). Only endocervical swab samples were tested. In 119 positive endocervical swab samples, from a total of 1600, the M. genitalium loads ranged between <300 and 3 240 000 copies/mL, with a limit of detection of 10 copies per reaction (or 300 copies/mL of cervical swab sample suspension). This limit was similar to that found by others in urine samples from male subjects [8] . This qPCR assay demonstrated good detection, reproducibility, and specificity and is useful for qualitative and quantitative analyses of M. genitalium in endocervical and probably other genital specimens [27] .
The new CE-marked multiplex real-time AmpliSens N. gonorrhoeae/C.trachomatis/M.genitalium/T.vaginalis-MULT-IPRIME-FRT PCR assay was evaluated and compared with 4 Aptima tests: the COMBO 2 assay, the Trichomonas vaginalis assay (FDA approved), and 2 different APTIMA M. genitalium RUO assays [28] , one of which was used for for discrepancy analysis. Overall, for M. genitalium, the multiplex AmpliSens PCR assay demonstrated 100% specificity, but suboptimal sensitivity (81.9%; 95% confidence interval, 70.7%-89.7%). These results were in concordance with characteristics of a singleplex AmpliSens M. genitalium PCR assay evaluated earlier. It is of interest that a lower sensitivity (76.5%) was obtained for vaginal samples, is in contrast to findings of many previous studies using other NAATs [28] .
A 2015 study documented a PCR-based microarray including 31 specific probes to simultaneously detect a diverse panel of 17 STI-associated infections, including N. gonorrhoeae, C. trachomatis, M. genitalium, M. hominis, Ureaplasma, herpes simplex virus types 1 and 2, and 10 human papillomavirus types [29] . The microarray was specific, because commensal and other closely related urogenital microbes did not cross-react with the microarray probes. It was 10 times more sensitive than multiplex PCR. Of 158 suspected human papillomavirus specimens evaluated, Ureaplasma was detected in 21, M. hominis in 15, C. trachomatis in 4, and N. gonorrhoeae in 1. However, no M. genitalium seemed to be detected. This research may be one of the first reports of a high-throughput detection system that identifies common pathogens associated with STIs from clinical samples [29] .
The fairly new Diagenode S-DiaMGTV qPCR commercial kit allows qualitative detection and differentiation of M. genitalium and T. vaginalis by qPCR in clinical specimens [30] . In a small study where the prevalence of Mycoplasma was 3.7%, it demonstrated almost perfect agreement with reference assays, and more studies will be welcome. One report compared the TIB MOLBIOL LightMix Kit and the Diagenode real-time PCR kit for M. genitalium with the in-house TaqMan RTPCR used routinely for the M. genitalium diagnostic [31] . Concordances of 96% and 93% were found for the TIB MOLBIOL and the Diagenode assays, respectively, compared with the results of the in-house assay.
Detection and Diagnosis of Antibiotic Resistance in M. genitalium
Mutations that confer antibiotic resistance to macrolides for M genitalium are concentrated in nucleotide positions 2058 and 2059 in region V of the 23S rRNA gene and are adenine to guanine, cytosine or thymidine transitions [18] . The locations of the 5 mutations that confer resistance are A2058G, A2058C, A2058T, A2059G, and A2059C. Jensen et al [18, 32] first described azithromycin failure in patients with M. genitalium associated with induced macrolide resistance and mutations in the region 23S rRNA gene. There have been several published research assays that can detect macrolide resistance in samples known to be positive for M. genitalium, using detection of the 23s rRNA gene mutations that are associated with resistance by PCR and melt curve analysis [32] [33] [34] [35] [36] . However, none of these assays are available commercially. All of these resistance studies confirm the high prevalence rate of mutations seen in other studies [24, 37] .
Normally, macrolide antibiotics such as azithromycin inhibit bacterial multiplication by binding to the 50S subunit of the ribosome, which includes both the 5S and 23S subunits to prevent translation of messenger RNA and prevent protein synthesis. Resistance occurs by the mutational changes that prevent binding of the antibiotic, and thus protein synthesis is not prevented, as would happen when the organism is sensitive to the antibiotic.
Getman et al [24] reported on the use of the CE-marked TMA assay (GenProbe/Hologic) to determine prevalence of M. genitalium infections. and coinfections with other sexually transmitted organisms and the frequency of a macrolide antibiotic resistance phenotype were determined in urogenital specimens collected from 946 care-seeking female and male subjects in the United States. Neither the ASR nor the CE-marked TMA assay detects the resistance mutations, but sequencing was used to assess macrolide antibiotic resistance among M. genitaliumpositive subjects in the study by Getman et al [24] . Prevalence rates for M. genitalium were 16.1% for female and 17.2% for male subjects. The macrolide-resistant phenotype was found in 50.8% of female and 42% of male subjects, confirming the high prevalence of resistance in other studies [32] [33] [34] [35] [36] [37] 
Need for Detection and Resistance Testing
With the rapid emergence of macrolide-resistant strains of M. genitalium [37] [38] [39] [40] [41] [42] [43] , it is recommended that all positive M genitalium assays be reflexed to a test to determine mutations for macrolide resistance. This can be performed by Sanger sequencing [32] , pyrosequencing [37] , high-resolution melt analysis [32] , or use of FRET probes [34, 35, 36] , A combination assay that can rapidly detect the organism and at the same time determine the molecular resistance markers for azithromycin, a standard antibiotic used for therapy, is desperately needed. One such assay recently developed is the 23S assay, which uses novel PlexZyme and PlexPrime technology (SpeeDX) [44] . A multiplex qPCR assay for detection of M. genitalium and the 5 mutations associated with macrolide resistance uses novel PlexZyme (formerly known as MNAzyme) technology and PlexPrimers that selectively amplify target Figure 1 . PlexPrimers are combined with PlexZymes for mutation-specific amplification and detection with quantitative polymerase chain reaction (qPCR). The PlexPrimer contains 3 sections; a long 5' target-recognition sequence (5T), a short 3' target-specific region (3T) matched to the mutation sequence (M) and an intervening insert sequence (INS), which does not bind to the target rather increases the specificity of the 3T region for the mutant over the wild type sequence. During amplification, the INS is incorporated into the PlexPrimer amplicons, and these can be detected in real time using PlexZymes, nucleic acid enzymes that form, from their component partzymes (A and B), only when matched PlexPrimer amplicons are present. Each partzyme contains a probe-binding arm, a partial catalytic core, and a target-binding arm, oriented such that partzyme A binds to the amplicon in the region containing the INS, and partzyme B binds adjacently downstream. Catalytically active PlexZymes bind and cleave reporter probes separating a fluorophore (F) and quencher (Q), resulting in signal generation. sequences, coupled to enable high-level multiplexing of mutant detection (Figure 1 ). The assay was evaluated in 400 samples from 254 consecutively infected participants, undergoing tests of cure. Of the M. genitalium-positive samples in the test of cure, 56% showed a macrolide resistance mutation. The MG 23S assay was compared with a reference qPCR method for M. genitalium detection and high-resolution melt analysis and sequencing for detection of macrolide resistance mutations; its sensitivity and specificity were 99.1% and 98.5% for M. genitalium detection and 97.4% and 100% for macrolide resistance. Recent use of this assay in our United States research studies has demonstrated similar high prevalence of macrolide resistance patterns: 50% in a prospective study and 36% in a retrospective study in over a total of 400 urogenital samples from female subjects (Justin Hardick, personal communication). The ability to diagnose M. genitalium infections and genetic markers for macrolide resistance simultaneously is a clinically important advance in new diagnostic test technology.
Moxifloxin is often recommended for treatment for patients in whom azithromycin fails, but fluoroquinolone resistance has now been well documented [39, 43, [45] [46] [47] . Microbiological failure of moxifloxacin treatment in patients has been associated with the detection of fluoroquinolone resistance-associated mutations in their clinical specimens [27] . If the resistance to moxifloxacin increases to high levels, it may be necessary to further develop diagnostic tests for detecting these resistance markers as well.
CONCLUSIONS
Currently, treatment of most M. genitalium infections occurs mainly in the context of syndromic management for urethritis, cervicitis, and PID, owing to the lack of diagnostic test availability in the United States. Testing is readily available in Europe but it is not clear how commonly it is used. A substantial body of clinical research based on RUO diagnostic assays has revealed much about the epidemiology and disease associations of M. genitalium. Now that we have learned that this organism is significantly associated with urethritis in men and significant morbid effects in women, including PID and increased susceptibility to human immunodeficiency virus infection, and that treatment with recommended antibiotics for the common STI syndromes often fail, it is time for further development of commercially available assays for use in diagnosing M. genitalium infection and guiding treatment decisions [45] . Determining the cost-effectiveness of widespread diagnosis of M. genitalium in symptomatic and asymptomatic high-risk individuals is urgently needed to drive this agenda forward, as are more commercially available, FDA-cleared assays.
Notes
